Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix intermittent androgen deprivation in prostate cancer
2008-003931-19Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Primary endpoint: Time to PSA greater than 4 ng/mL during first intermittent androgen deprivation cycle. Started Jul 2008; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-003931-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003931-19.